scholarly journals Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome—A Systematic Review

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2291 ◽  
Author(s):  
Zhang ◽  
Mocanu ◽  
Cai ◽  
Dang ◽  
Slater ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Insulin Sensitivity ◽  
Body Mass ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Metabolic Parameters ◽  
Fasting Plasma

Fecal microbiota transplantation (FMT) is a gut microbial-modulation strategy that has been investigated for the treatment of a variety of human diseases, including obesity-associated metabolic disorders. This study appraises current literature and provides an overview of the effectiveness and limitations of FMT as a potential therapeutic strategy for obesity and metabolic syndrome (MS). Five electronic databases and two gray literature sources were searched up to 10 December 2018. All interventional and observational studies that contained information on the relevant population (adult patients with obesity and MS), intervention (receiving allogeneic FMT) and outcomes (metabolic parameters) were eligible. From 1096 unique citations, three randomized placebo-controlled studies (76 patients with obesity and MS, body mass index = 34.8 ± 4.1 kg/m2, fasting plasma glucose = 5.8 ± 0.7 mmol/L) were included for review. Studies reported mixed results with regards to improvement in metabolic parameters. Two studies reported improved peripheral insulin sensitivity (rate of glucose disappearance, RD) at 6 weeks in patients receiving donor FMT versus patients receiving the placebo control. In addition, one study observed lower HbA1c levels in FMT patients at 6 weeks. No differences in fasting plasma glucose, hepatic insulin sensitivity, body mass index (BMI), or cholesterol markers were observed between two groups across all included studies. While promising, the influence of FMT on long-term clinical endpoints needs to be further explored. Future studies are also required to better understand the mechanisms through which changes in gut microbial ecology and engraftment of microbiota affect metabolic outcomes for patients with obesity and MS. In addition, further research is needed to better define the optimal fecal microbial preparation, dosing, and method of delivery.

Abstract #713: Age Dependent Relationship Between Body Mass Index and Fasting Plasma Glucose in South-Western Nigeria

2016 ◽  
Vol 22 ◽  
pp. 152-153
Author(s):  
Taiwo Raimi ◽  
Olatunde Odusan ◽  
Olufemi Fasanmade ◽  
Adesina Odewabi ◽  
Augustine Ohwovoriole
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Dependent Relationship ◽  
Fasting Plasma ◽  
Age Dependent

scholarly journals Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose

2010 ◽  
Vol 163 (4) ◽  
pp. 573-583 ◽  
Author(s):  
Petr Wohl ◽  
Eva Krušinová ◽  
Martin Hill ◽  
Simona Kratochvílová ◽  
Kateřina Zídková ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Insulin Sensitivity ◽  
Impaired Fasting Glucose ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Fasting Glucose ◽  
Substrate Utilization ◽  
Metabolic Effects ◽  
Plasma Adiponectin ◽  
Fasting Plasma

ObjectiveTelmisartan improves glucose and lipid metabolism in rodents. This study evaluated the effect of telmisartan on insulin sensitivity, substrate utilization, selected plasma adipokines and their expressions in subcutaneous adipose tissue (SAT) in metabolic syndrome.Design and methodsTwelve patients with impaired fasting glucose completed the double-blind, randomized, crossover trial. Patients received telmisartan (160 mg/day) or placebo for 3 weeks and vice versa with a 2-week washout period. At the end of each period, a hyperinsulinemic euglycemic clamp (HEC) combined with indirect calorimetry was performed. During HEC (0, 30, and 120 min), plasma levels of adipokines were measured and a needle biopsy (0 and 30 min) of SAT was performed.ResultsFasting plasma glucose was lower after telmisartan compared with placebo (P<0.05). There were no differences in insulin sensitivity and substrate utilization. We found no differences in basal plasma adiponectin, resistin and tumour necrosis factor α (TNFα), but an increase was found in basal leptin, after telmisartan treatment. Insulin-stimulated plasma adiponectin (P<0.05), leptin and resistin (P<0.001) were increased, whereas TNFα was decreased (P<0.05) after telmisartan treatment. Expression of resistin, but not adiponectin, TNFα and leptin was increased after telmisartan treatment.ConclusionsDespite the decrease in fasting plasma glucose, telmisartan does not improve insulin sensitivity and substrate utilization. Telmisartan increases plasma leptin as well as insulin-stimulated plasma adiponectin, leptin and resistin, and decreases plasma TNFα during HEC. Changes in plasma adipokines cannot be explained by their expressions in SAT. The changes in plasma adipokines might be involved in the metabolic effects of telmisartan in metabolic syndrome.

scholarly journals Effect of body mass index on diabetogenesis factors at a fixed fasting plasma glucose level

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0189115 ◽  
Author(s):  
Jiunn-Diann Lin ◽  
Chun-Hsien Hsu ◽  
Chung-Ze Wu ◽  
An-Tsz Hsieh ◽  
Chang-Hsun Hsieh ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Glucose Level ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Plasma Glucose Level ◽  
Fasting Plasma Glucose Level ◽  
Fasting Plasma

scholarly journals Serum Secretogranin III Concentrations Were Increased in Subjects with Metabolic Syndrome and Independently Associated with Fasting Plasma Glucose Levels

2019 ◽  
Vol 8 (9) ◽  
pp. 1436 ◽  
Author(s):  
Chun-Chung Lin ◽  
Kai-Pi Cheng ◽  
Hao-Chang Hung ◽  
Chung-Hao Li ◽  
Ching-Han Lin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Pancreatic Beta Cells ◽  
Secretory Granules ◽  
High Sensitivity ◽  
Metabolic Parameters ◽  
Glucose Levels ◽  
Fasting Plasma ◽  
High Fasting Plasma Glucose

Secretogranin III (SCG3) plays a crucial role in the biogenesis of secretory granules in endocrine cells, and thus affects glucose homeostasis by regulating insulin secretion by pancreatic beta cells. Insulin resistance and compensatory hyperinsulinemia are hallmarks of metabolic syndrome (MetS). However, the role of SCG3 in MetS remains unclear. Therefore, we investigated the relationship between serum SCG3 levels and metabolic parameters in subjects with and without MetS. This was a case control study, and 295 subjects were recruited. Serum SCG3 concentrations were compared between groups. Associations between SCG3 levels and clinico-metabolic parameters were also examined. We found serum SCG3 levels were higher in the MetS group than non-MetS group (122.6 ± 79.2 vs. 90.6 ± 58.5 nmol/L, p = 0.009). Specifically, elevated SCG3 levels were found in subjects with high fasting plasma glucose (FPG) levels, central obesity, or hypertriglyceridemia. Additionally, MetS was an independent factor of serum SCG3 levels in multivariate linear regression analyses. Moreover, FPG, free fatty acids, and waist circumference were positively associated with serum SCG3 concentrations after adjusting for insulin levels, high-sensitivity C-reactive protein, and cardiovascular risk factors. In conclusion, serum SCG3 concentrations were higher in subjects with MetS and were independently associated with FPG levels.

scholarly journals Correction: Effect of body mass index on diabetogenesis factors at a fixed fasting plasma glucose level

PLoS ONE ◽  
2018 ◽  
Vol 13 (5) ◽  
pp. e0197212
Author(s):  
Jiunn-Diann Lin ◽  
Chun-Hsien Hsu ◽  
Chung-Ze Wu ◽  
An-Tsz Hsieh ◽  
Chang-Hsun Hsieh ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Glucose Level ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Plasma Glucose Level ◽  
Fasting Plasma Glucose Level ◽  
Correction Effect ◽  
Fasting Plasma

Thyroid function is associated with body mass index and fasting plasma glucose in Thai euthyroid population

2019 ◽  
Vol 13 (1) ◽  
pp. 468-473 ◽  
Author(s):  
Amornpan Lertrit ◽  
La-or Chailurkit ◽  
Boonsong Ongphiphadhanakul ◽  
Wichai Aekplakorn ◽  
Chutintorn Sriphrapradang
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Thyroid Function ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Fasting Plasma
Sign in / Sign up

Export Citation Format

Share Document